|
Khan O, La Thangue, Kerr et al. "HR23B is a biomarker for tumour sensitivity to HDAC inhibitor-based therapy." Proc Nat Acad Science –107(14):6532-7. 2010.
Rahman N M, Davies HE, Salzberg M, Truog P, Midgely R, Kerr D, Clelland C, Hedley EL, Lee YCG, Davies RJO. Use of lipoteichoic acid-T for pleurodesis in malignant pleural eff usion: a phase I toxicity and dose-escalation study. Lancet Oncology. 2008. 1016/S1470-2045(08)70205-5.
Middleton M, Knox C, Cattell E, Opperman U, Ali R, Auton T, Agarwal R, Anderson D, Sarker D, Judson I, Osawa T, Harlley J and Kerr DJ. Quinone Oxido-reductase-2-mediated Prodrug Cancer Therapy. Science Translational Medicine, 2, 420-428, 2010
Edwards AM, Bountra C, Kerr DJ, Willson TM. Open access chemical and clinical probes to support drug discovery. Nat Chem Biol. 2009 Jul;5(7):436-40
Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R, Boivin C, Hesslewood S, Twelves C, Calver H, Lind M, Robbins A, Burtles S, Duncan R and Cassidy J. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. International Journal of Oncology. 2009 Jun;34(6):1629-36.
Midgley R, Kerr D, Flaherty K, Stevenson JP, Pratap S, Koch K, Smith D, Versola M, Fleming R, Ward C, O'Dwyer P and Middleton M. A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Annals of Oncology 2007 18(12):2025-2029.
Swaisland HC, Smith RP, Laight A, Kerr DJ, Ranson M, Wilder-Smith CH, Duvauchelle T. Single-dose clinical pharmacokinetic studies of gefitinib. Clinical Pharmacokinetics. 2005;44(11):1165-77
Kerr DJ, La Thangue N. Signal transduction blockade and cancer : combination therapy or multi-targeted inhibitors? Annals of Oncology, 15: 1727-1729, 2004
Danson S, Ferry D, Alkhov V, Margison J, Kerr D, Jowle D, Brampton M, Halbert G and Ranson M. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. British Journal of Cancer. 2085-2091,2004
Knox RJ, Burke PJ, Chen S, Kerr DJ. CB 1954: from the Walker tumor to NQO2 and VDEPT. Curr Pharm Des. 2003;9(26):2091-104.
Milner AE, Palmer DH, Hodgkin EA, Eliopoulos AG, Knox PG, Poole CJ, Kerr DJ, Young LS. Induction of apoptosis by chemotherapeutic drugs: the role of FADD in activation of caspase-8 and synergy with death receptor ligands in ovarian carcinoma cells. Cell Death Differ 2002;9(3):287-300
Seymour, L.W., Ferry, D.R., Anderson, D., Doran,J, Young, A.M., Kerr, D.J., Hesselwood,S., Julyan, P.J., Poyner, R. and Burtles, S., Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin J-Clin-Oncol. 2002 Mar 15; 20(6): 1668-76
Taylor,-P-M; Woodfield,-R-J; Hodgkin,-M-N; Pettitt,-T-R; Martin,-A; Kerr,-D-J; Wakelam,M.J. Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway. Oncogene. 2002 Aug 22; 21(37): 5765-72
Mulholland PJ, Ferry DR, Anderson D, Hussain SA, Young AM, Cook JE, Hodgkin E, Seymour LW, Kerr DJ. Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. Annals of Oncology 2001;12(2):245-248
Ferry DR, Deakin M, Baddeley J, Daryanani S, Bramhall S, Anderson DA, Wakelam MJO, Doran J, Pemberton G, Young AM, Buckels J & Kerr DJ. A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: Correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. Annals of Oncology, 11, 1165-1170 (2000).
Julyan PJ, Seymour LW, Ferry DR, Daryani S, Boivin CM, Doran J, David M, Anderson D, Christodoulou C, Young AM, Hesslewood S and Kerr DJ. Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. Journal of Controlled Release 1999; 57.281-90.
Anderson, D., Ferry, D.R., Knox,R.J., Andrews, S.J., Downes, A.J., Kerr, D.J., and Seymour, L.W. (1999). High-performance chromatographic method for sensitive determination of the alkylating agent CB1954 in human plasma. Journal of Chromatography B 731, 293-298.
Harper, A., Kerr, D.J., Gescher, A., and Chipman, J.K. (1999). Antioxidant effects of isofavonoids and lignans, and protection against DNA oxidation. Free Radical Research 31, 149-160.
Harper A, Kerr DJ, Gescher A and Chipman JK. Antioxidant effects of isoflavonoids and lignans, and protection against DNA oxidation. Free Radical Res., 31, 149-160 (1999)
Murray LS, Jodrell DI, Morrison JG, Cook A, Kerr DJ, Whiting B, Kaye SB, Cassidy J. The effect of Cimetidine on the pharmacokinetics of Epirubicin in patients with advanced breast cancer: preliminary evidence of a potentially common drug interaction. Clinical Oncology 10:35-38 (1998)
Helsby NA, Chipman JK, Gescher A and Kerr DJ. Inhibition of mouse and human CYP 1A-and 2E1-dependent substrate metabolism by the isoflavonoids Genistein and Equol. Food and Chemical Toxicology, 36, 375-382 (1998)
Schultze-Mosgau M, Dale IL, Gant TW, Chipman JK, Kerr DJ and Gescher A. Regulation of c-fos transcription by chemopreventive isoflavonoids and lignans in MDA-MB-468 breast cancer cells. Europ. J. Cancer,Vol 34 : 9, 1425-1431 (1998)
Helsby NA, Chipman JK, Gescher A and Kerr D. Inhibition of carcinogen-activating cytochrome P450s by potential chemopreventative agents genistein and equol. Food Chem. Toxicol. 36, 568-577
Christodoulou CV, Eliopoulos AG, Young LS, Hodgkins L, Ferry DR and Kerr DJ. Anti-proliferative activity and mechanism of action of titanocene dichloride. British Journal of Cancer 77(12: 2088-2097 (1998)
Christodoulou CV, Ferry DR, Fyfe DW, Young A, Doran J, Sheehan TMT, Elipoulos A, Hale K, Baumgart J, Sass G, Kerr David J. Phase I Trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer. J. Clin. Oncol 16: 8 2761-2769 (1998)
Julyan PJ, Seymour LW, Ferry DR, Daryani S, Boivin CM, Doran J, David M, Anderson D, Christodoulou C, Young AM, Hesslewood S Kerr DJ. Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. Journal of Controlled Release 57: 281-290 (1998)
Anderson, D; Kerr, DJ; Blesing, C; Seymour, LW Simultaneous gas chromatographic-mass spectrophotometric determination of a-fluoro-b-alanine and 5-fluorouracil in plasma. J Chromatogr. 688, 87-93 (1997)
Helsby NA, Williams, J, Kerr, D, Gescher, A, Chipman, JK. The isoflavones equol and genistein do not induce xenobiotic-metabolising enzymes in mouse and in human cells.Xenobiotica, Vol. 27, 6: 587-596 (1997)
Cross MJ, Hodgkin MN, Plumb JA, Brunton VG, Stewart A, MacAully G, Hill R, Kerr DJ, Workman P, Wakelam MJO. Inhibition of phospholipid signalling and proliferation of Swiss 3T3 cells by the wortmannin analogue demethoxyviridin. Biochimica et Biophysica ACT 1362 29-38 (1997)
Helsby NA, Williams J, Kerr D, Gescher A and Chipman JK. The isoflavones equol and genistein do not induce xenobiotic-metabolising enzymes in mouse and in human cells. Xenobiotica 27, 587-596 (1997)
Seymour, LW; Shoaibi, MA; Martin, A; Ahmal, A; Elvin, P; Kerr, DJ and Wakelam MJO Vascular endothelial growth factors stimulates protein kinase C dependent phospholipase D activity in endothelial cells. Lab.Invest. 75 3, 427-437 (1996)
Ferry, DR; Smith, A; Malkhandi, J; Fyfe, DW; de Takats, PG; Anderson, D; Baker, J; Kerr, DJ Phase I trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clinical Cancer Res 2: 659-668 (1996)
Eliopoulos AG, Dawson CW, Mosialos G, Floettmann J Eike, Rowe M, Armitage, RJ, Dawson J, Zapata JM, Kerr DJ, Wakelam MJO, Reed JC, Kieff E and Young LS. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene (1996) 13, 2243-2254 (1996)
Eliopoulos, AG; Kerr, DJ; Herod, J; Hodgkins, L; Krajewski, S; Reed, JC; Young, LS The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11: 1217-1228 (1995)
Eliopoulos, AG; Kerr, DJ; Maurer, HR; Hilgard, P; Spandidos, DA. Induction of the c-myc but not the cH-ras promoter by platinum compounds. Biochem Pharmacol 50 1: 33-38 (1995)
Ferry, DR; Malkhandi, PJ; Russell, MA; Kerr, DJ. Allosteric regulation of [3H]vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldipine. Biochem Pharmacol 49 12: 1851-1861(1995)
Cross, MJ; Stewart, A; Hodgkin, MN; Kerr, DJ; Wakelam, MJO. Wortmannin and its structural analogue demethoxyviridin inhibit stimulated phospholipase A2 activity in swiss 3T3 cells. J of Biological Chem, 270 43: 25352-25355 (1995)
Liu, B; Anderson, D; Ferry, DR; Seymour, LW; de Takats, PG; Kerr, DJ.Determination of quercetin in human plasma using reverse-phase high-performance liquid chromatography. J Chromatography B, 666: 149-155 (1995)
Liu, B; Earl, HM; Poole, CJ; Dunn, J; Kerr, DJ Etoposide protein binding in cancer patients. Cancer Chemother Pharmacol 36: 506-512 (1995)
Liu, B; Earl, HM; Baban, DF; Shoaibi, M; Fabra, A; Kerr, DJ; Seymour, LW Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Comm 217 3: 721-727. (1995)
Ferry, DR; Kerr, DJ Multidrug resistance in cancer. Br Med J 308: 148-149 (1994)
Malkhandi, J; Ferry, DR; Boer, R; Gekeler, V; Ise, W; Kerr, DJ. Dexniguldipine-HCl is a potent allosteric inhibitor of [3H]vinblastine binding to P-glycoprotein of CCRF ADR 5000 cells. Eur J Pharmacol Mol. Pharmacol. Section 288: 105-114 (1994)
Wishart GC; Bissett, D; Paul, J; Jodrell, D; Harnett, A; Habeshaw, T; Kerr, DJ; Macham, MA; Soukop, M; Leonard, RCF, Knepil, J; Kaye, SB Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo controlled randomized trial. J Clin Oncol 12 9: 1771-1777 (1994)
Cross, MJ; Stewart, A; Plumb, J; Mcauley, G; Hill, RA; Isaacs, N; Workman, P; Kerr, D; Wakelam, MJO Inhibition of phospholipases and cell proliferation by demethoxyviridin. J Cellular Biochem. S18D: 56 (1994)
Kerr, DJ. Phase I clinical trials: adapting methodology to face new challenges. Annals Oncol 5 4: S67-S70 (1994)
Morrison, JG; Bissett, D; Stephens, IFD; McKay, K; Brown, R; Graham, MA; Fichtinger-Schepman,AM; Kerr, DJ. The isolation and identification of cis-diamminedichloroplatinum II-DNA adducts by anion exchange HPLC and inductively coupled plasma mass spectrometry. Int J Oncology 2: 33-37 (1993)
Plumb, JA; Luo, W; Kerr, DJ. Effect of polyunsaturated fatty-acids on the drug sensitivity of human tumour cell lines resistant to either cisplatin or doxorubicin. Br J Cancer 67 4: 728-733 (1993)
Kerr,DJ; Los,G. Ph armacokinetic principles of locoregional chemotherapy. Cancer Surveys 17: 105-122 (1993)
Bissett, D; Setonoians, A; Cassidy, J; Graham, M; Chadwick, GA; Wilson, P; Auzanet, V; LeBail, N; Kaye, SB; Kerr, DJ. Phase I and pharmacokinetic study of taxotere RP 56976 administered as a 24-hour infusion. Cancer Res 53: 523-527 (1993)
Cassidy, J; Graham, MA; Huinink, WT; McDaniel, C; Setanoians, A; Rankin, EM; Kerr, DJ; Kaye, SB for the EORTC ECTG. Phase I clinical study of LL-D49194a1 with retrospective pharmacokinetic investigations in mice and humans. Cancer Chemother Pharmacol 31 5: 395-400 (1993)
Zoumpourlis, V; Kerr, DJ; Spandidos, DA. Differential Interaction of Cisplatin with the HIV-1 long terminal repeat in a resistant ovarian carcinoma cell line. Anti-Cancer Drugs 4: 77-83 (1993)
Dunlop, DJ; Wright, EG; Lawrence, S; Graham, GJ; Holyoake, T; Kerr, DJ; Wolfe, SD; Pragnell, IB. Demonstration of Stem cell inhibition and myeloprotective effects of SCI/rhMIPIa in vivo. Blood 79 9: 2221-2225. 1992
Bisset, D; Graham, MA; Setanoians, A; Chadwick, GA; Wilson, P; Koier, R; Henrar, R; Schwartsmann, G; Cassidy, J; Kaye, SB; Kerr, DJ. Phase I and pharmacokinetic study of rhizoxin. Cancer Res 52: 2894-2898. 1992
Wade, JR; Kelman, AW; Kerr, DJ; Robert, J; Whiting, B Variability in the pharmacokinetics of epirubicin : a population analysis. Cancer Chemother Pharmacol 29: 391-395. 1992
Zoumpourlis, V; Kerr, DJ; Spandidos, DA Carboplatin as opposed to cisplatin does not stimulate the expression of the human immunodeficiency virus long terminal repeat sequences. Biochem Pharmacol 43 3: 650-654. 1992
Bissett, D; Kaye, SB; Kerr, DJ. Can primary osteosarcoma act as a third space after high dose methotrexate?. Eur J Cancer 27: 1060. 1992
Goldberg, JA; Willmott, N; Kerr, DJ; Sutherland, C; McArdle, CS. An in vivo assessment of adriamycin-loaded albumin microspheres. Br J Cancer 65: 393-395. 1992
Scott, RN; Blackie, R; Kerr, DJ; Hughes, J; Burnside, G; MacKie, RM; Byrne, DS; McKay, AJ Melphalan concentration and distribution in the tissues of tumour-bearing limbs treated by isolated limb perfusion. Eur J Cancer 28a 11: 1811-1813. 1992
Scott, RN; Kerr, DJ; Blackie, R; Hughes, J; Burnside, G; MacKie, RM; Byrne, DS; McKay, AJ The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma. Br J Cancer. 66: 159-166. 1992
Cassidy, J; Bissett, D; Kerr, DJ. Methodological aspects of phase I studies of novel anti-cancer agents Review. Int J Oncol 1: 195-199. 1992
Graham, MA; Bissett, D; Setanoians, A; Kerr, DJ. Pre-clinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme. J National Cancer Inst 84: 494-500. 1992
Bissett, D; Kerr, DJ; Cassidy, J; Meredith, P; Traugott, U; Kaye, SB Phase I and pharmacokinetic study of D-verapamil and doxorubicin. Br J Cancer 64: 1168-1171. 1991
Eliopoulos, A; Kerr, DJ; Spandidos, DA. The effect of doxorubicin, daunorubicin and 4’-epidoxorubicin on the exogenous c-myc promoter in mouse erythroleukaemia cells. Anticancer Res 11: 2153-2158. 1991
Graham, MA; Riley, RJ; Kerr, DJ. Drug metabolism in carcinogenesis and cancer chemotherapy. Pharmac Ther 51: 275-289. 1991
Kaye, SB; Kerr, DJ. Multidrug resistance : Clinical relevance in haematological malignancies. Blood Reviews 6: 39-42. 1991
Zoumpourlis, V; Kerr, DJ; Spandidos, DA. Doxorubicin stimulates transcription from the human immunodeficiency virus long terminal repeat sequences. Cancer Letters 56: 181-185. 1991
Goldberg, JA; Kerr, DJ; Blackie, R; Whately, TL; Pettit, L; Kato, T; McArdle, CS.Mitomycin C-loaded microcapsules in the treatment of colorectal liver metastases. Cancer 67: 952-955. 1991
Goldberg, JA; Murray, T; Kerr, DJ; Willmott, N; Bessent, RG, McKillop, JH; McArdle, CS.The use of angiotensin II as a potential method of targeting cytotoxic microspheres in patients with intrahepatic tumour. Br J Cancer 63: 308-310. 1991
Cytotoxic-loaded microspheres in patients with colorectal liver metastases.Br J Cancer 64: 114-119. 1991
Kerr, DJ; Kaye, SB.Chemoembolism in cancer chemotherapy. Critical Reviews in Therapeutic Drug Carrier Systems 8 1: 19-37. 1991
Eliopoulos, A; Kerr, DJ; Spandidos, DA The effect of cisplatin and carboplatin on c-myc promoter in erythroleukaemic cells. Anticancer Drugs 2: 597-601. 1991
Kerr, DJ; Plumb, JA; Freshney, RI; Khan, MZ; Spandidos, DA The effect of H-ras oncogene transfection on response of mink lung epithelial cells to growth factors and cytotoxic drugs. Anticancer Res 11: 1349-1352. 1991
Wishart, GC; Plumb, JA; Spandidos, DA; Kerr, DJ H-ras transfection in mink lung epithelial cells may induce “atypical” multidrug resistance. Eur J Cancer 27 5: 673. 1991
Anderson, JH; Goldberg, JA; Eley, JG; Whateley, TL; Kerr, DJ; Cooke, TG; McArdle,CS A Phase I study of regionally administered mitomycin microcapsules for patients with colorectal liver metastases.Eur J Cancer 27 9: 1189-1190. 1991
Thomson, AM; Kerr, DJ; Steel, CM Transforming growth factor b1 is implicated in the failure of Tamoxifen therapy in human breast cancer. Br J Cancer, 63: 609-614. 1991
Jones, RD; Kerr, DJ; Harnett, AN; Rankin, EM; Ray, S; Kaye, SB. A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer. Br J Cancer 62: 133-135. 1990
Kerr, DJ; Kaye, SB. Multidrug resistance in haematological malignancies. Haematology Reviews 4: 61-64. 1990
Kerr, DJ; Khan, MZ; Plumb, JA; Freshney, RI; Spandidos, DA. The effect of oncogene transfection on epithelial cell response to cytotoxic drugs. Biochem Pharmacol 9: 375-379. 1990
Goldberg, JA; Kerr, DJ; Stewart, I; McArdle, CS. A comparison of regional and systemic chemotherapy for hepatic metastases.Eur J Surg Oncol 16: 464-467. 1990
Goldberg, JA; Kerr, DJ; Willmott, N; McKillop, J; McArdle, CS. Regional chemotherapy for colorectal liver metastases : a phase II evaluation of targeted hepatic arterial 5-fluorouracil for colorectal liver metastases.Br J Surgery 77: 1238-1240. 1990
Carmichael, J; Cantwell, KA; Mannix, KA; Veale, D; Elford, HL; Blackie, R; Kerr, DJ; Kaye, SB; Harris, AL.A phase I and pharmacokinetic study of didox admistered by 36 hour infusion. Br J Cancer 61: 447-450. 1990
Kerr, DJ; Slack, JA; Secrett, P; Stevens, MFG; Blackledge, GRP; Bradley, C; Kaye, SB. Relationships between the pharmacokinetics and toxicity of mitozolamide. Cancer Chemother Pharmacol 25: 352-354. 1990
Kerr, DJ; Lewis, C; O'Neil, B; Lawson, N; Blackie, R; Newell, DR; Roball, F; Cox, J; Rankin, EM; Kay, SB The myelotoxicity of carboplatin is influenced by the time of its administration. Haematol Oncol 8: 54-65. 1990
Goldberg, JA; Kerr, DJ; Watson, DG; Willmott, N; Bates, CD; McKillop, JH; McArdle, CS The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.Br J Cancer 62: 78-85. 1990
Lewis, C; Lawson, N; Rankin, EM; Morrison, G; MacLean, AB; Cordiner, J; Cassidy, J; Kerr, DJ; Kaye, SB Phase I and pharmacokinetic study of intraperitoneal thioTEPA in patients with ovarian cancer.Cancer Chemother Pharmacol 26: 283-287. 1990
Cummings, J; Double, JA; Bibby, M; Farmer, P; Evans, S; Kerr, DJ; Kaye, SB; Smyth, JF. Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice. Cancer Res 49: 3587-3593. 1989
Kerr, DJ; Kaye, SB. Flavone acetic acid - preclinical and clinical activity. Eur J Cancer Clin Oncol 25 9: 1271-1272. 1989
Kerr, DJ; Pragnell, IB; Sproul, A; Cowan, S; Murray, T; George, D; Leake, R The cytostatic effects of a-interferon may be mediated by transforming growth factor-b. J Molec Endocrin 2: 131-136. 1989
Kerr, DJ; Maughan, T; Newlands, E; Rustin, G; Bleehen, NM; Lewis, C; Kaye, SB. Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma. Br J Cancer 60: 104-106. 1989
Kerr, DJ; Hynds, S; Shepherd, J; Packard, CJ; Kaye, SB. Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers. Biochem Pharmacol 37 20: 3981-3986. 1988
Kerr, DJ; Rogerson, A; Morrison, GJ; Florence, AT; Kaye, SB. Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer, spheroid and xenograft. Br J Cancer 58: 432-436. 1988
Kerr, DJ; Wheldon, TE; Hynds, S; Kaye, SB. Cytotoxic drug penetration studies in multicellular tumour spheroids. Xenobiotica, 18 6: 641-648. 1988
Goldberg, JA; Fenner, J; Bradnam, MS; Bessent, RG; McKillop, JH; Kerr, DJ; McArdle, CS.Improved tumour targeting of biodegradable microspheres with angiotensin II. Br J Surgery 75 12:1262. 1988
Goldberg, JA; Kerr, DJ; Willmott, N; McKillop, JH; McArdle, CS.Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil 5FU in advanced colorectal liver metastases.Br J Cancer 57: 186-189. 1988
Kerr, DJ; Willmott, N; Levi, H; McArdle, CS.The pharmacokinetics and disposition of adriamycin loaded albumin microspheres following intra renal arterial administration.Cancer 62: 878-882. 1988
McArdle, CS; Lewis, H; Hansell, D; Kerr, DJ; McKillop, J; Willmott, N.Cytotoxic loaded albumin microspheres : a novel approach to regional chemotherapy.Br. J Surg 75: 132-134. 1988
Gouyette, A; Kerr, DJ; Kaye, SB; Setanoians, A; Cassidy, J; Bradley, C; Forrest, G; Soukop, M. Flavone acetic acid : a non linear pharmacokinetic model. Cancer Chemother Pharmacol 22: 114-119. 1988
Goldberg, JA; Kerr, DJ; Willmott, N; McArdle, CS; Murray, T; Hilditch, T Increased uptake of radiolabelled microspheres with angiotensin II in colorectal hepatic metastases. Eur J Surgical Oncol 14: 715. 1988
Kerr, DJ; Harding, M; Amarin, J; Farmer, J; Blackie, RG; Kaye, SB The pharmacokinetics of CHIP in patients with impaired renal function and following intraperitoneal administration.Oncology and Tumour Pharmacotherapy 5 3: 153-158. 1988
Veale, D; Carmichael, J; Cantwell, BMJ; Elford, HL; Blackie, R; Kerr, DJ; Kaye, SB; Harris, AL A phase I and pharmacokinetic study of didox : A ribonucleotide reductase inhibitor. Br J Cancer 58: 70-72. 1988
Goldberg, JA; Fenner, J; Bessent, RG; Bradnam, MS; McKillop, JH; McKee, RF; McArdle, CS; Kerr, DJ.Clinical evaluation of angiotensin II enhanced perfusion scintigraphy in metastatic liver disease. Nuclear Med Comm 10: 557-566. 1988
Cummings,-J; Kerr,-D-J; Kaye,-S-B; Smyth,-J-F. Optimisation of a reversed-phase high-performance liquid chromatographic method for the determination of flavone acetic acid and its major human metabolites in plasma and urine. J-Chromatogr. 1988 Sep 23; 431(1): 77-85
Goldberg, JA; Bradnam, MS; Kerr, DJ; Haughton, DM; McKillop, JH;Bessent, RG; Willmott, N; McArdle, CS; George, WD Arterio-venous shunting of microspheres in patients with colorectal liver metastases: errors in assessment due to free pertechnetate and the effect of angiotensin II.Nuclear Med Comm 8: 1033-1046. 1987
Goldberg, JA; Bradnam, MS; Kerr, DJ; McKillop, JH; Bessent, RG; McArdle, CS; Willmott, N; George, WD Single photon emission computed tomographic studies SPECT of hepatic arterial perfusion scintigraphy HAPS in patients with colo- rectal liver metastases : improved targeting by tumour microspheres with angiotensin II. Nuclear Med Comm 8: 1025-1032. 1987
Cummings, J; Willmott, N; More, I; Kerr, DJ; Lewi, HJ; McKillop, J. Comparitive cardiotoxicity and antitumour activity of doxorubicin adriamycin and 4'-deoxydoxorubicin and the relationship to in vivo disposition and metabolism in the target tissues. Biochemical Pharmacology 36 9: 1521-1526. 1987
Cummings, J; Kerr DJ; Kaye, SB. Occurrence of circulating 7-deoxyaglycone metabolites of 4'-deoxydoxorubicin in man. Cancer Chemother Pharmacol 20: 263-264. 1987
Kerr, DJ; Kaye, SB; Cassidy, J; Bradley, C; Rankin, EM; Adams, L; Setonoians, A; Young, T; Forrest, G; Soukop, M; Clavel, M. Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res 47: 6776-6781. 1987
Cummings, J; Kerr, DJ; Kaye, SB Occurrence of circulating 7-deoxyaglycone metabolites of 4'-deoxydoxorubicin in man. Cancer Chemother Pharmacol 20: 263-264. 1987
Cummings, J; Willmott, N; More, I; Kerr, DJ; Gilmour, J; Morrison, JG; Kaye, SB.Comparative cardiotoxicity and antitumour activity of doxorubicin adriamycin and 4'-deoxydoxorubicin and the relationship to in vivo disposition and metabolism in the target tissues.Biochem Pharmacol 36 9: 1521-1526. 1987
Kerr, DJ.Microparticulate vehicles as cytotoxic drug carriers. Cancer Drug Delivery 4 1: 55-60. 1987
Kerr, DJ; Kaye, SB.Aspects of cytotoxic drug penetration, with particular reference to anthracyclines.Cancer Chemother Pharmacol 19: 1-5. 1987
Kerr, DJ; Kerr, AM; Wheldon, TE; Kaye, SB.In vitro chemosensitivity testing using the multicellular tumour spheroid model. Cancer Drug Delivery 4 2: 124-130. 1987
Kerr, DJ; Wheldon, TE; Russell, JG; Maurer, HR; Florence, AT; Halbert, GW; Freshney, RI; Kaye, SB.The effect of the non-ionic surfactant Brij 30 on the cytotoxicity of adriamycin in monolayer, spheroid and clonogenic culture systems. Eur J Cancer Clin. Oncol. 23 9: 1315-1322. 1987
Kerr, DJ; Wheldon, TE; Kerr, AM; Freshney, RI; Kaye, SB. The effect of adriamycin and 4'-deoxydoxorubicin on cell survival on human lung tumour cells grown in monolayer and as spheroids. Br J Cancer, 54: 423-429. 1986
Kerr, DJ; Kaye, SB; Graham, J; Cassidy, J; Harding, M; Setanoians, A; McGrath, JC; Vezin, WR; Cunningham, D; Forrest, G; Soukop, M. Phase I and pharmacokinetic study of LM985. Cancer Res 46: 3142-3246. 1986
Kerr, DJ; Graham, J; Cummings, J; Morrison, JG; Thompson, GG; Brodie, MJ; Kaye, SB The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 18: 239-242. 1986
Kaye, SB; Cummings, J; Kerr, DJ. How much does liver disease affect the pharmacokinetics of adriamycin? Eur J Cancer Clin Oncol 21 8: 893-895. 1985
Kerr, DJ; Graham, J; Blackie, RG; Cunningham, D; Kaye, SB. The relationship between steady-state plasma levels of metoclopramide and control of cis-platinum induced emesis. Br J Pharmacol 20: 426-427. 1985
Kerr, DJ; Kerr, AM; Freshney, I; Kaye, SB. Comparative intracellular uptake of adriamycin and 4'-deoxydoxorubicin by non-small cell lung tumor cells in culture and its relationship to cell survival. Biochem Pharmacol 35 16: 2817-2823. 1985
Kaye,S.B; Cummings,J; Kerr,D.J. How much does liver disease affect the pharmacokinetics of adriamycin? Eur.J.Cancer.Clin.Oncol. 1985 Aug; 21(8): 893-5
Share with your friends: |
